Cryptosporidiosis and the challenges of chemotherapy

Drug Resistance Updates

Volumn 5, Issue 1, 2002, Pages 47-57

  Mead, Jan R ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; Cryptosporidum; Drug resistance

Indexed keywords

ACRIDINE DERIVATIVE; ANILINE DERIVATIVE; ANTIINFECTIVE AGENT; ANTIRETROVIRUS AGENT; AZITHROMYCIN; BENZIMIDAZOLE; BUPARVAQUONE; CLARITHROMYCIN; DICLAZURIL; DIHYDROFOLATE REDUCTASE INHIBITOR; FATTY ACID SYNTHASE; LETRAZURIL; MACROLIDE; NITAZOXANIDE; PAROMOMYCIN; POLYAMINE; PYRONE DERIVATIVE; ROXITHROMYCIN; SHIKIMIC ACID; SPIRAMYCIN; TRIFLURALIN; ANTIFUNGAL AGENT;

CHEMOTHERAPY; COLOSTRUM; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM PARVUM; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RESEARCH; DRUG SOLUBILITY; DRUG TARGETING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE CYCLE; NONHUMAN; PRIORITY JOURNAL; REVIEW; ZOONOSIS; ANIMAL; ANTIBIOTIC RESISTANCE; CELL MEMBRANE; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MICROBIOLOGY; PHYSIOLOGY;

ANIMALS; ANTIFUNGAL AGENTS; CELL MEMBRANE; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM PARVUM; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, FUNGAL; HUMANS;

EID: 0036462586     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-7646(02)00011-0     Document Type: Article

References (102)

1. Infections of the gastrointestinal tract
2. A comparison of the effects of two dinitroanilines against Cryptosporidium parvum in vitro and in vivo in neonatal mice and rats
3. In vitro anticryptosporidial activity of dinitroaniline herbicides
4. Polyamine metabolism
5. Inhibition of cytoplasmic and organellar protein synthesis in Toxoplasma gondii. Implications for the target of macrolide antibiotics
6. Synthesis and evaluation of dinitroanilines for treatment of cryptosporidiosis
7. Prophylaxis and chemotherapy: Human and animal
8. Inhibition of Cryptosporidium parvum in neonatal Hsd:(ICR)BR Swiss mice by polyether ionophores and aromatic amidines
9. Comparative efficacy evaluation of dicationic carbazole compounds, nitazoxanide, and paromomycin against C. parvum infections in a neonatal mouse model
10. Pilot studies of azithromycin, letrazuril and paromomycin in the treatment of cryptosporidiosis
11. Identification of Cryptosporidium parvum dihydrofolate reductase inhibitors by complementation in Saccharomyces cerevisiae
12. Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy
13. Cryptosporidium is more closely related to the gregarines than to coccidia as shown by phylogenetic analysis of apicomplexan parasites inferred using small-subunit ribosomal RNA gene sequences
14. Cryptosporidiosis
15. Nitazoxanide in the treatment of cryptosporidial diarrhea and other intestinal parasitic infections associated with acquired immunodeficiency syndrome in tropical Africa
16. Symptoms and transmission of intestinal cryptosporidiosis
17. Cryptosporidium and microsporidial beta-tubulin sequences: Predictions of benzimidazole sensitivity and phylogeny
18. Paromomycin is effective as prophylaxis for Cryptosporidiosis in diary cattle
19. Activity of benzimidazoles against cryptosporidiosis in neonatal BALB/c mice
20. Efficacy of hyperimmune bovine colostrum for prophylaxis of cryptosporidiosis in neonatal calves
21. Rifabutin but not clarithromycin prevents cryptosporidiosis in persons with advanced HIV infection
22. A plastid organelle as a drug target in apicomplexan parasites
23. Cryptosporidiosis
24. Clinical and microbiological effects of bovine anti-Cryptosporidium immunoglobulin (BACI) on cryptosporidial diarrhea in patients with AIDS
25. Efficacy of nitazoxanide, tizoxanide and tizoxanide glucuronide against Cryptosporidium parvum development in sporozoite-infected HCT-8 enterocytic cells
26. In-vitro activity of macrolides alone and in combination with artemisin, atovaquone, dapsone, minocycline or pyrimethamine against C. parvum
27. Efficacy of treatment with paromomycin, azithromycin, and nitazoxanide in a patient with disseminated cryptosporidiosis
28. Activity of buforin II alone and in combination with azithromycin and minocycline against Cryptosporidium parvum in cell culture
29. Diagnose und therapie der akuten kryptosporidiose beim kalb
30. Cryptosporidiosis: An outbreak associated with drinking water despite state-of-theart water treatment
31. Treatment of severe diarrhea caused by C parvum with oral bovine immunoglobulin concentrate in patients with AIDS
32. Paromomycin and geneticin inhibit intracellular Cryptosporidium parvum without trafficking through the host cell cytoplasm implications for drug delivery
33. A phase I study of letrazuril in AIDS-related cryptosporidiosis
34. Therapeutic efficacy of paromomycin in immunosuppressed adult mice infected with Cryptosporidium parvum
35. Paromomycin: No more effective than placebo for treatment of cryptosporidiosis in patients with advanced human immunodeficiency virus infection
36. Possible effectiveness of clarithromycin and rifabutin for cryptosporidiosis chemophylaxis in HIV disease
37. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART) in a London clinic
38. Hyperimmune bovine colostrum specific for recombinant Cryptosporidium parvum antigen confers partial protection against cryptosporidiosis in immunosuppressed adult mice
39. Confirmation of the prophylactic value of paromomycin in a natural outbreak of caprine cryptosporidiosis
40. Clarithromycin prophylaxis against Cryptosporidium enteritis in patients with AIDS
41. A new approach for targeting to Cryptosporidium parvum using mucoadhesive nanosuspensions: Research and applications
42. Evaluation of in vitro activity of aurones and related compounds against Cryptosporidium parvum
43. Antiprotozoal activities of benzimidazoles and correlations with beta-tubulin sequence
44. Polyamine biosynthesis in C. parvum and its implications for chemotherapy
45. Chemotherapeutic effect of azithromycin and lasalocid on Cryptosporidium infection in mice
46. Plasmodium vivax: In vitro antiparasitic effect of cyclosporins
47. Characterization of an intestinal epithelial cell receptor recognized by the Cryptosporidium parvum sporozoite ligand CSL
48. Intestinal and extraintestinal cryptosporidiosis in AIDS patients
49. Massive outbreak of waterborne Cryptosporidium infection in Milwaukee, Wisconsin: Recurrence of illness and risk of secondary transmission
50. Chemoprophylaxis of Cryptosporidium parvum infection with paromomycin in kids and immunological study
51. Evaluation of maduramicin and alborixin in a SCID mouse model of chronic cryptosporidiosis
52. Food-related illness and death in the United States
53. Improved efficacy of dinitroaniline analogs for use as anti-cryptosporidial drugs
54. Eradication of cryptosporidia and microsporidia following successful antiretroviral therapy
55. Treatment with bovine hyperimmune colostrum of cryptosporidial diarrhea in AIDS patients
56. Cryptosporidium and cryptosporidiosis in man and animals
57. Prophylactic effect of bovine anti-Cryptosporidium hyperimmune colostrum immunoglobulin in healthy volunteers challenged with Cryptosporidium parvum
58. Virulence of three distinct Cryptosporidium parvum isolates for healthy adults
59. The ABC transporter genes of Plasmodium falciparum and drug resistance
60. Characterization of an ATP-binding cassette transporter in Cryptosporidium parvum
61. CpABC, a Cryptosporidium parvum ATP-binding cassette protein at the hostparasite boundary in intracellular stages
62. Immunotherapy of cryptosporidiosis in immunodeficient animal models
63. Protection of calves against cryptosporidiosis with immune bovine colostrum induced by a Cryptosporidium parvum recombinant protein
64. Treatment of intestinal cryptosporidiosis with spiramycin
65. Anti-cryptosporidial activity of macrolides in immunosuppressed rats
66. Activity of azithromycin against cryptosporidia in immunosuppressed rats
67. Protective monoclonal antibody defines a circumsporozoite-like glycoprotein exoantigen of Cryptosporidium parvum sporozoites and merozoites
68. Preliminary evidence for a mitochondrion in Crytposporidium parvum: Phylogenetic and theraputic implications
69. Evidence for the shikimate pathway in apicomplexan parasites
70. The role of drugs in the control of parasitic nematode infections: Must we do without?
71. A double-'blind' placebo-controlled study of nitazoxanide in the treatment of cryptosporidial diarrhoea in AIDS patients in Mexico
72. Treatment of diarrhea caused by Cryptosporidium parvum: A prospective randomized, double-blind, placebo-controlled study of Nitazoxanide
73. Eradication of Cryptosporidium in a child undergoing maintenance chemotherapy for leukemia using high dose azithromycin therapy
74. Spiramycin vs. placebo for treatment of acute diarrhea caused by Cryptosporidium
75. Oral administration of bovine colostrum anti-cryptosporidiosis antibody fails to alter the course of human cryptosporidiosis
76. Characterization of anti-Toxoplasma activity of SDZ 215-918, a cyclosporin derivative lacking immunosuppressive and peptidyl-prolyl-isomerase-inhibiting activity: Possible role of a P glycoprotein in Toxoplasma physiology
77. Combination drug therapy for cryptosporidiosis in AIDS
78. Treatment strategies for cryptosporidiosis
79. AIDS-related cryptosporidial diarrhoea: An open study with roxithromycin
80. The treatment of cryptosporidiosis in AIDS patients using paromomycin
81. Inhibition of Toxoplasma gondii replication by dinitroaniline herbicides
82. Gene discovery in Cryptosporidium parvum: Expressed sequence tags and genome survey sequences
83. Efficacy of nitazoxanide against Cryptosporidium parvum in cell culture and in animal models
84. Dinitroaniline herbicides against protozoan parasites: The case of Trypanosoma cruzi
85. Remission of diarrhea due to cryptosporidiosis in an immunodeficient child treated with hyperimmune bovine colostrum
86. Evaluation of a two-phase scid mouse model preconditioned with anti-interferon-γ monoclonal antibody for drug testing against Cryptosporidium parvum
87. Roxithromycin treatment for diarrhoea caused by Cryptosporidium spp. in patients with AIDS
88. Cessation of Cryptosporidium-associated diarrhea in an acquired immunodeficiency syndrome patient after treatment with hyperimmune bovine colostrum
89. Azithromycin for treatment of severe Cryptosporidium diarrhea in two children with cancer
90. Potential antifolate resistance determinants and genotypic variation in the bifunctional dihydrofolate reductase-thymidylate synthase gene from human and bovine isolates of Cryptosporidium parvum
91. Efficacy of halofuginone lactate against Cryptosporidium parvum in calves
92. Field trial on the therapeutic efficacy of paromomycin on natural Cryptosporidium parvum infections in lambs
93. Accelerated inflammatory bowel disease of TCR-α deficient mice persistently infected with Cryptosporidiumparvum
94. [(1)N,(12)N]Bis(Ethyl)-cis-6,7-dehydrospermine: A new drug for treatment and prevention of Cryptosporidium parvum infection of mice deficient in T-cell receptor α
95. Paromomycin for cryptosporidiosis in AIDS: A prospective, double-blind trial
96. Extrachromosomal DNA in the Apicomplexa
97. Spiramycin is not effective in treating Cryptosporidium diarrhea in infants: Results of a double-blind randomized trial
98. Efficacy of 101 antimicrobials and other agents on the development of Cryptosporidium parvum in vitro
99. In-vitro activities of paromomycin and lasalocid evaluated in combination against C. parvum
100. What is the phylogenetic position of Cryptosporidium?
101. Cryptosporidium parvum appears to lack a plastid genome
102. Molecular analysis of a type I fatty acid synthase in Cryptosporidium parvum